Latest Europe News

Camplify Holdings Limited reported a 12.3% revenue decline to $42.1 million and a near doubling of net loss to $15.8 million in FY25, reflecting a year of strategic transformation including the launch of its MyWay protection product and completion of European platform integration.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

RAS Technology Holdings reports a robust 31% revenue increase in FY25, marking its second consecutive profitable year, driven by strategic acquisitions and global partnerships that position it for sustained growth.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Perpetual Limited reported a steady underlying profit for FY25, achieving significant cost savings while navigating asset management outflows and advancing the sale of its Wealth Management division.

AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.

Ramsay Health Care reported a 6.8% revenue increase and a modest rise in underlying profit for FY25, despite a significant impairment in its UK mental health division. The company maintains a strong dividend and outlines a cautiously optimistic outlook for FY26.

Atlas Arteria reported a 32.9% drop in statutory net profit for H1 2025 due to a new French tax, yet achieved solid toll revenue and EBITDA growth, maintaining its 2025 distribution guidance.